mTOR inhibition enhances synaptic and mitochondrial function in Alzheimer’s disease in an APOE genotype-dependent manner
Sanganahalli B, Mihailovic J, Vekaria H, Coman D, Yackzan A, Flemister A, Aware C, Wenger K, Hubbard W, Sullivan P, Hyder F, Lin A. mTOR inhibition enhances synaptic and mitochondrial function in Alzheimer’s disease in an APOE genotype-dependent manner. Cerebrovascular And Brain Metabolism Reviews 2024, 44: 1745-1758. PMID: 38879800, PMCID: PMC11494852, DOI: 10.1177/0271678x241261942.Peer-Reviewed Original ResearchResponse to rapamycinE3FAD miceMitochondrial functionAlzheimer's diseaseMammalian target of rapamycinAD genetic risk factorsApolipoprotein E4Neuronal mitochondrial functionMitochondrial oxidative metabolismE4FAD miceHuman APOE4 geneTCA cycle rateGenetic risk factorsGenotype-dependent mannerE3FADTarget of rapamycinAPOE4 geneAPOE3 alleleGlutamate-glutamine cycleAPOE4 carriersBioenergetic measurementsE4FADMetabolic functionsAPOE genotypeMammalian target of rapamycin inhibition